Rohit Aggarwal, MD
Rheumatology · Pittsburgh, PANPI 1538340138
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $623,406 of the $810,294 with a category attached, or 76.9%. It is spread thinly across 33 manufacturers, the largest accounting for just 19.5%. 2025 is the largest year on record at $197,126, 4.4 times the $45,223 reported in 2019. Among rheumatology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 368 payments — averaging $2201.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$158K
- Pfizer$122K
- CSL Behring$84K
- AstraZeneca$72K
- Octapharma USA, Inc.$70K
- Astrazeneca UK Limited$56K
- plus $248K from 27 others
Across 18 payments — averaging $304,961 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$4.9M
- E.r. Squibb & Sons, L.L.C.$284K
- Mallinckrodt Hospital Products Inc.$176K
- Mallinckrodt Enterprises LLC$106K
- Octapharma USA, Inc.$62K
- Pfizer$6K
- plus $5K from 1 others
What the payments were for
- Consulting fees$623,40677%
- Speaking & faculty fees$83,46910%
- Travel & lodging$97,81712%
- Food & beverage$5,6021%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 25 | $158,396 |
| Pfizer | 29 | $122,410 |
| CSL Behring | 34 | $84,219 |
| AstraZeneca(2 entities) | 27 | $71,652 |
| Octapharma USA, Inc. | 58 | $69,594 |
| Astrazeneca UK Limited | 13 | $55,541 |
| E.r. Squibb & Sons, L.L.C. | 39 | $53,093 |
| Boehringer Ingelheim | 36 | $35,616 |
| Boehringer Ingelheim International GmbH | 17 | $32,937 |
| Novartis | 20 | $30,556 |
| Argenx US, Inc. | 13 | $25,885 |
| Bristol Myers Squibb | 9 | $13,110 |
| EMD Serono, Inc. | 3 | $10,013 |
| Merck | 8 | $8,002 |
| AbbVie | 1 | $6,750 |
| ANI Pharmaceuticals, Inc. | 5 | $5,906 |
| Janssen Global Services, LLC | 3 | $5,010 |
| Eli Lilly | 5 | $3,776 |
| UCB SA | 1 | $3,420 |
| Amgen | 1 | $2,744 |
| Sanofi | 1 | $2,292 |
| EMD Serono Research & Development Institute, Inc. | 1 | $2,213 |
| Jubilant Draximage Inc. | 1 | $2,000 |
| GSK | 3 | $1,998 |
| Teva Pharmaceuticals USA, Inc. | 1 | $1,408 |
| Beigene, Ltd. | 1 | $620 |
| Sobi, Inc | 6 | $504 |
| Vertex | 1 | $375 |
| Medtronic | 1 | $123 |
| Sun Pharmaceutical Industries Inc. | 1 | $87 |
| Johnson & Johnson | 1 | $17 |
| Lilly USA, LLC | 1 | $14 |
| Stratus Medical, LLC | 2 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$810,294 in reported general payments places this provider in the 95th percentile of 351 rheumatology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 13 | $397,308 |
| Humira(Cf) PenAdalimumab | 36 | $325,673 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 39 | $255,647 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 28 | $245,816 |
| Xeljanz XrTofacitinib Citrate | 25 | $142,812 |
| Actemra ActpenTocilizumab | 26 | $124,954 |
| Humira(Cf)Adalimumab | 18 | $124,948 |
| XeljanzTofacitinib Citrate | 22 | $122,680 |
| RituxanRituximab | 12 | $113,288 |
| KevzaraSarilumab | 15 | $63,478 |
| Mycophenolate Mofetil | 99 | $18,311 |
| Tacrolimus | 16 | $6,585 |
| Hydroxychloroquine Sulfate | 165 | $6,409 |
| MethotrexateMethotrexate Sodium | 192 | $6,382 |
| Cevimeline Hcl | 16 | $5,622 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerOctagam, Xeljanz | $122,410 | $519,98935 claims |
| CSL BehringHizentra | $84,219 | $245,81628 claims |
| AbbVieHumira(Cf) | $6,750 | $124,94818 claims |
| SanofiKevzara | $2,292 | $63,47815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 351 rheumatology providers in Pennsylvania.
Other rheumatology in Pittsburgh
- Susan ManziPittsburgh$67K
- Michael LuckePittsburgh$51K
- Chester OddisPittsburgh$38K
- Daniella SchwartzPittsburgh$38K
- Lindsay LedwichPittsburgh$37K
- Robyn DomsicPittsburgh$28K
- Ghassan AlayliPittsburgh$24K
- Tanmayee BichilePittsburgh$24K
- Alan EpsteinPhiladelphia$1.2M
- Lawrence LeventhalHuntingdon Valley$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.